The long-term goal of the Cancer Genetics and Epigenetics (CGE) Program is to pursue basic research on fundamental cellular processes relevant to cancer biology and to seek opportunities for translating the resulting information into clinical use. To this end, the following Specific Goals will be pursued: 1. Identify the molecular processes by which genomic instability is generated and contributes to oncogenesis;2. Explore how epigenetic modifications of DMA and chromatin influence tumor initiation and progression;and 3. Elucidate the mechanisms underlying control of cell division and ascertain how these mechanisms are abrogated in cancer. The CGE Program is one of the two Basic Science Programs of the HICCC. In replacing the former Developmental Biology &Genetics Program it has been restructured to increase cancer relevance, and the heightened cancer focus of the new CGE Program is reflected by a 400% increase in NCI funding. The Program pursues its scientific goals by promoting interactions among CGE investigators and with other HICCC members, encouraging collaborative research projects and joint grant proposals, and providing a forum in which CGE investigators share their latest discoveries and consider the clinical value of their basic research findings. Potential clinical applications include identification and analysis of environmental toxins, modified therapeutic regimens to accommodate """"""""radiation bystander"""""""" effects, development of biodosimetry, use of nanofluidic cassettes (""""""""biochips"""""""") in diagnostic/predictive laboratory assays (including monitoring therapeutic responses), high-throughput screening to identify small molecules that modulate malignant processes, and pre-clinical testing of these molecules for therapeutic effects. The CGE Program consists of 32 members (all full members of the HICCC) from eleven departments at Columbia University. The Program is supported by several collaborative efforts, including a recently renewed, five-year $5.2M (direct costs) program project grant from the NCI entitled """"""""Radiation Bystander Effects: Mechanisms"""""""" (P.I., Tom Hei). For the last budget year of the grant (July 1, 2006 - June.30, 2007), the CGE Program received a total of $17.12M (direct costs) in cancer-relevant grant support, including $3.69M (direct costs) in NCI funding, $12.95M (direct costs) in other cancer-related peer-reviewed funding, and $0.48M (direct costs) in cancer-related non-peer-reviewed funding. The total number of cancer-related publications by the current Program members since the previous submission (i.e., 2003-present) was 330, with 17.0% inter-programmatic and 12.4% intra-programmatic publications.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Columbia University (N.Y.)
New York
United States
Zip Code
Villasante, A; Sakaguchi, K; Kim, J et al. (2017) Vascularized Tissue-Engineered Model for Studying Drug Resistance in Neuroblastoma. Theranostics 7:4099-4117
Ma, Kevin K; Lin, James; Boudreault, Katherine et al. (2017) PHENOTYPING CHOROIDEREMIA AND ITS CARRIER STATE WITH MULTIMODAL IMAGING TECHNIQUES. Retin Cases Brief Rep 11 Suppl 1:S178-S181
Kampers, Johanna; Orjuela-Grimm, Manuela; Schober, Tilmann et al. (2017) Classical Hodgkin lymphoma-type PTLD after solid organ transplantation in children: a report on 17 patients treated according to subsequent GPOH-HD treatment schedules. Leuk Lymphoma 58:633-638
Cabral, Thiago; DiCarlo, James E; Justus, Sally et al. (2017) CRISPR applications in ophthalmologic genome surgery. Curr Opin Ophthalmol 28:252-259
Velez, Gabriel; Bassuk, Alexander G; Colgan, Diana et al. (2017) Therapeutic drug repositioning using personalized proteomics of liquid biopsies. JCI Insight 2:
Dutta, Aditya; Panja, Sukanya; Virk, Renu K et al. (2017) Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5?-reductase Inhibition. Eur Urol 72:499-506
Chiang, Wei-Chieh; Chan, Priscilla; Wissinger, Bernd et al. (2017) Achromatopsia mutations target sequential steps of ATF6 activation. Proc Natl Acad Sci U S A 114:400-405
Marks, Lianna J; Oberg, Jennifer A; Pendrick, Danielle et al. (2017) Precision Medicine in Children and Young Adults with Hematologic Malignancies and Blood Disorders: The Columbia University Experience. Front Pediatr 5:265
Kanner, Scott A; Morgenstern, Travis; Colecraft, Henry M (2017) Sculpting ion channel functional expression with engineered ubiquitin ligases. Elife 6:
Wang, Tian; Tsang, Stephen H; Chen, Jeannie (2017) Two pathways of rod photoreceptor cell death induced by elevated cGMP. Hum Mol Genet 26:2299-2306

Showing the most recent 10 out of 263 publications